I am starting to believe that IPIX operates in a realm closely resembling a ninja. We are building a massive case for wildly successful drugs (especially Brilacidin at the current time) in plain sight of everyone but nobody appears to have noticed.
I do not take this as a lack of management skills nor a conscious attempt by medicine to trivialize IPIX and our products. It is simply that IPIX has not reached the point with its drugs to have merited much notice to date, at least as far as big medicine is concerned.
One of the most eye opening posts ever was just recently made when it was revealed by a poster that his relative, a high executive at a major NYC hospital, told him that they don't even become aware of a product prior to verifiable data as evidenced by peer reviewed articles or results of human trials. Company PRs mean nothing to them.
Thus, though we on this board know (or at least we think we know) everything about Brilacidin for CV and other indications, we have not yet reached the point that big medicine has become aware of us.
That point is rapidly approaching and we have planned well for it with the appointment today of Dr. DeGrado as a scientific advisor, the recent SI results of 300+ for Brilacidin vs CV19, many tests run by the government's own regional bio lab that were so impressive that the lab co-applied with us for a PAN-CORONA grant, prior ABSSSI human trials reflecting the safety of B, etc. We have steadily built our position, but step by step it has gone under the radar of big medicine and seemingly big government.
That will be changing soon when the RBL results are published, the pre-peer review article is published, grant money is received from the government, and a human trial is finalized.
Even all the above may still leave Brilacidin under the radar somewhat as we never know what news big media will run with and they may ignore B for the time being.
But the results of the human trials, and IMO even earlier the indications from early patients (maybe only a day or two after receiving the B IV) will give a very good indication that B is extremely effective as a CV19 treatment.
This is what will blow the minds of big medicine IMO. If we get wide publicity prior to this, great, but I am only interested in how B is viewed after the human trial patients react to it.
I am extremely confident at that time our stock price will rise tremendously. Until then, still at the mercy of the MMs and algorithms that seem to be intent on keeping the IPIX share price at the current levels.
So let IPIX continue to add to its arsenal and even if these continuing successes seem to go unnoticed, know that soon every small step forward will prove of major importance to the tremendous acceptance by big medicine to Brilacidin.
Keep the eye on the war, not on the battle. If IPIX were a fighter, it would have landed MANY body shots thru the early and mid rounds but has yet to land the killer blow. But as we near the final rounds, all those body blows already landed will prove to be the catalyst for IPIX to launch a haymaker against anyone standing against Brilacidin.
I do not take this as a lack of management skills nor a conscious attempt by medicine to trivialize IPIX and our products. It is simply that IPIX has not reached the point with its drugs to have merited much notice to date, at least as far as big medicine is concerned.
One of the most eye opening posts ever was just recently made when it was revealed by a poster that his relative, a high executive at a major NYC hospital, told him that they don't even become aware of a product prior to verifiable data as evidenced by peer reviewed articles or results of human trials. Company PRs mean nothing to them.
Thus, though we on this board know (or at least we think we know) everything about Brilacidin for CV and other indications, we have not yet reached the point that big medicine has become aware of us.
That point is rapidly approaching and we have planned well for it with the appointment today of Dr. DeGrado as a scientific advisor, the recent SI results of 300+ for Brilacidin vs CV19, many tests run by the government's own regional bio lab that were so impressive that the lab co-applied with us for a PAN-CORONA grant, prior ABSSSI human trials reflecting the safety of B, etc. We have steadily built our position, but step by step it has gone under the radar of big medicine and seemingly big government.
That will be changing soon when the RBL results are published, the pre-peer review article is published, grant money is received from the government, and a human trial is finalized.
Even all the above may still leave Brilacidin under the radar somewhat as we never know what news big media will run with and they may ignore B for the time being.
But the results of the human trials, and IMO even earlier the indications from early patients (maybe only a day or two after receiving the B IV) will give a very good indication that B is extremely effective as a CV19 treatment.
This is what will blow the minds of big medicine IMO. If we get wide publicity prior to this, great, but I am only interested in how B is viewed after the human trial patients react to it.
I am extremely confident at that time our stock price will rise tremendously. Until then, still at the mercy of the MMs and algorithms that seem to be intent on keeping the IPIX share price at the current levels.
So let IPIX continue to add to its arsenal and even if these continuing successes seem to go unnoticed, know that soon every small step forward will prove of major importance to the tremendous acceptance by big medicine to Brilacidin.
Keep the eye on the war, not on the battle. If IPIX were a fighter, it would have landed MANY body shots thru the early and mid rounds but has yet to land the killer blow. But as we near the final rounds, all those body blows already landed will prove to be the catalyst for IPIX to launch a haymaker against anyone standing against Brilacidin.
9
